SSA
GRCE

Schonfeld Strategic Advisors’s Grace Therapeutics GRCE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-604
Closed -$71K – 1586
2019
Q4 		$71K Buy
+604
New +$59.7K ﹤0.01% 1221

Other funds holding GRCE

Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JLBC
J.L. Bainbridge & Co Sarasota, Florida $1.27B AUM 26.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Schonfeld Strategic Advisors's GRCE Position: Q1 2020 in Review

Schonfeld Strategic Advisors sold out of Grace Therapeutics (GRCE) in Q1 2020, closing a stake of 604 shares — an estimated $71K sold.

Schonfeld Strategic Advisors first reported a position in GRCE in Q4 2019 and held it in 1 quarter. The position peaked at $71K in Q4 2019. 26 funds tracked by Wall St. Rank hold GRCE as of Q1 2020.

  • Schonfeld Strategic Advisors reported no remaining Grace Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 604 Grace Therapeutics shares in Q1 2020, an estimated $71K.
  • Schonfeld Strategic Advisors first reported a position in Grace Therapeutics in Q4 2019 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Grace Therapeutics position peaked at $71K in Q4 2019.
  • 26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2020, filed 15 May 2020.